Karachi: Liven Pharma Limited has reported a robust financial performance for the period ending August 18, 2025, driven by operational efficiencies and sustained demand within the pharmaceutical sector. The company achieved a turnover of PKR 120.79 million and gross profit rose to PKR 38.032 million, which reflects effective cost management and enhanced production efficiencies. The profit after tax stood at PKR 110.855 million.
Liven Pharma remains committed to strengthening its financial position by collaborating with multinational corporations worldwide and introducing innovative products to the Pakistani market. The recent decrease in the KIBOR rate is expected to significantly reduce the company's financing costs, enhancing profitability and cash flow management.
According to information available from the Pakistan Stock Exchange (PSX), the company is gearing up for its imminent expansion into the commercial market, aiming to unlock new revenue streams and strengthen its market presence. With the pharmaceutical sector experiencing steady demand and the company's ongoing commitment to innovation, quality, and operational efficiency, Liven Pharma is well-positioned to achieve sustained growth in the coming periods.
Liven Pharma's management is focused on capitalizing on emerging opportunities and enhancing shareholder value by introducing multinational companies as technical and new product partners. They are also preparing to acquire an API manufacturing plant for dynamic growth. The company expressed gratitude for the cooperation and continuous support provided by regulatory authorities, shareholders, customers, vendors, employees, and other stakeholders.
The company’s total assets amounted to PKR 977.53 million, while its equity and liabilities were divided between PKR 895.91 million in total equity and PKR 83.03 million in total liabilities. The designated market category remains the pharmaceutical sector, reflecting the company's ongoing initiatives to maintain its competitive edge and expand its market footprint.